Skip to content

FDA Delays Review of New Actos Combo Drug

The Federal Drug Administration delayed review of a Takeda Pharmaceuticals drug that is combined with Actos, a diabetes medication that has been linked to bladder cancer. Actos was approved by…

The Federal Drug Administration delayed review of a Takeda Pharmaceuticals drug that is combined with Actos, a diabetes medication that has been linked to bladder cancer. Actos was approved by the FDA in 1999 but recently was determined to be harmful.

Takeda, headquartered in Japan, boasted Actos as a safe alternative to other diabetes medications that caused strokes and heart attacks. The reports say the drug will start to give patients bladder cancer in as little as 12 months.

“Actos is a member of a class of drugs known as thiazolidinediones, which have been linked to bladder cancer,” the US Drug Watchdog said in a released statement. “Actos side effects include increased risk of congestive heart failure, and an increased risk for bladder cancer.”

Lawsuits were first filed against Takeda in August 2011. Have you or a loved one been injured or killed due to a defective product or medication?

Wooten, Kimbrough & Normand, P.A.—Orlando personal injury attorneys.

Orman Kimbrough

Orman Kimbrough

Orman Kimbrough has represented thousands of people, some catastrophically injured, because of the negligence of others and malfunctioning products. As of 2020, Mr. Kimbrough has retired.

All articles
Tags: Health

More in Health

See all

More from Orman Kimbrough

See all